tiprankstipranks
Biogen responds to Committee on Oversight, stands by ‘integrity’ of actions
The Fly

Biogen responds to Committee on Oversight, stands by ‘integrity’ of actions

Biogen issued the following corporate statement on the House Committee on Oversight report: "Since 2021 Biogen has been working cooperatively with the U.S. House Committee on Oversight and Reform and the U.S. House Energy and Commerce Committee regarding their investigations into the launch of Aduhelm, including providing requested information… Biogen has been committed to researching and developing treatments for Alzheimer’s disease for more than a decade. We have been focused relentlessly on innovation to address this global health challenge, and have adapted to both successes and setbacks. Biogen stands by the integrity of the actions we have taken. As stated in the congressional report, an FDA review concluded that, ‘There is no evidence that these interactions with the sponsor in advance of filing were anything but appropriate in this situation.’ Alzheimer’s is a highly complex disease and we have learned from the development and launch of Aduhelm. That process is continuing to inform our work as Biogen introduces new innovative treatments to the market. We will continue to appropriately engage diverse stakeholders at every step, including patients and their families, health care providers, and the scientific community. We are dedicated to our mission of bringing innovative and transformative treatments to patients with serious and hard-to-treat conditions." Reference Link

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on BIIB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles